Spero Therapeutics (SPRO) Receivables - Other (2016 - 2025)
Spero Therapeutics' Receivables - Other history spans 10 years, with the latest figure at $28000.0 for Q4 2025.
- For Q4 2025, Receivables - Other fell 99.09% year-over-year to $28000.0; the TTM value through Dec 2025 reached $28000.0, down 99.09%, while the annual FY2025 figure was $28000.0, 99.09% down from the prior year.
- Receivables - Other reached $28000.0 in Q4 2025 per SPRO's latest filing, down from $1.6 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $8.5 million in Q1 2021 to a low of $28000.0 in Q4 2025.
- Average Receivables - Other over 5 years is $2.5 million, with a median of $2.0 million recorded in 2023.
- Peak YoY movement for Receivables - Other: skyrocketed 347.54% in 2021, then plummeted 99.09% in 2025.
- A 5-year view of Receivables - Other shows it stood at $2.6 million in 2021, then tumbled by 58.95% to $1.1 million in 2022, then surged by 42.53% to $1.5 million in 2023, then soared by 99.68% to $3.1 million in 2024, then tumbled by 99.09% to $28000.0 in 2025.
- Per Business Quant, the three most recent readings for SPRO's Receivables - Other are $28000.0 (Q4 2025), $1.6 million (Q3 2025), and $2.5 million (Q2 2025).